WASHINGTON, March 14 (TNSFR) -- The Food and Drug Administration (FDA) has issued a final order permanently debarring Bernardo Garmendia, also known as Bernardo Germendia, from providing services in any capacity to entities with approved or pending drug product applications. The decision follows Garmendia's conviction for conspiracy to commit wire fraud related to falsified clinical trial data at AMB Research Center, Inc., a Florida-based medical clinic conducting drug trials.

. . .

Click here for more information about our products